Pediatric Asthma eYardstick CME

The Pediatric Asthma eYardstick presents an in-depth model including practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma. This interactive version is designed to enable practitioners to intuitively and efficiently utilize the yardstick model in an office setting. 

Price: FREE for members and non-members

You might also like:

Atopic Dermatitis eYardstick
Anaphylaxis eParameter
PIDD eParameter

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 2.5 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Target Audience

Practicing Allergy/Immunology Providers and Fellows in Training.

Learning Objectives

  • Use the Pediatric Asthma yardstick to understand and diagnose the type, level of severity, and control of patients' asthma
  • Based on that analysis understand where the patient falls on the asthma yardstick
  • Understand options of management and control based on their step
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 Attendance
Course opens: 
10/17/2022
Course expires: 
10/16/2025
Rating: 
0

Available Credit

  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 Attendance
Please login or create an account to take this course.